Cambridge, England, United Kingdom
Commercial leader with more than 20 years of broad pharmaceutical experience in sales, marketing, strategic operations and commercial capabilities. Strong track record across varying roles both at the local and global levels. Diverse therapeutic area experience to include respiratory, cardiovascular, diabetes, neuroscience, analgesia, gastrointestinal, anti-infective and women’s health. Extensive commercial experience including new product launches, established brands, life-cycle management, mergers and alliance management. Ability to think and influence strategically, build strong cross-functional relationships, and drive performance in complex and dynamic environments.
Led the annual revenue forecast cycle based upon insights and input from key focus markets; budget management reprioritizing brand investments to drive initiatives aligned to strategy. Global marketing lead for EU; ensuring consistent execution of the strategy, new data launch readiness, commercial excellence, performance analysis and facilitating best practices sharing across region in relevant forums.
Commercial lead on the global cross-functional, market shaping, Act on COPD program; driving the global organisation towards a full comprehension of the program and its long term vision; launched ‘Be Flare Aware’, a global patient activation campaign that was selected as a finalist for the 2023 Communiqué Awards. Global marketing lead for COPD launch execution in EU & China; co-developing commercialisation plans and working closely with the local country team to ensure launch readiness and launch success, with China delivering the highest ICS/LABA/LAMA market share globally (75%). Commercial lead on a cross-functional team for a Phase 3 trial that received investment prioritisation from SET.
Leading the marketing function of the Biopharmaceutical Business Unit comprising Cardiovascular, Diabetes, Renal, Respiratory and Gastrointestinal portfolio with >$65mil in sales turnover, and ensuring launch readiness for Renal franchise. Member of the country leadership team. • Member of a cross-country taskforce for the Accelerate! Programme, an International region programme co-developed with Center for Creative Leadership and INSEAD Business School. • Contributing as subject matter expert for Asia Area BUD Development Centre. • Member of the Asia Area Marketing Excellence taskforce to uplift marketing capabilities across Asia Area.
Responsible for delivering the customer-facing initiatives, and internal capability building for the company’s infant nutrition business, with a team of five Medical & Scientific Affairs Manager and Regional Nutritionists. Key achievements: • Established structure for the department, with defined processes and tools to support achievement of department and company’s goals. • Established training framework for new recruits and existing team members to uplift standard of technical knowledge. • Partnered with key opinion leaders to establish the Clinical Practice Guidelines in Management of Cow’s Milk Protein Allergy in 2012.
Progressing from sales to marketing with increasing responsibility for various therapeutic areas including CV, Pain, Diabetes and Women's Health. Responsible for two direct reports. Key achievements: • Integrated the Schering Plough oral contraceptive business into MSD post-merger. • Launched Januvia, first-in-class DPP-4 inhibitor, and became the best launch oral anti-diabetic drug at that time; grew revenue by 10-fold within two years. • Launched Arcoxia within three weeks of regulatory approval, creating a record as the brand with the most rapid time from approval to market; established market leadership within two years of launch.